bryce tenbarge  progenics pharmaceuticals  inc  zoominfocom bryce tenbarge  progenics pharmaceuticals  inc  zoominfocom pgnx bryce v tenbarge insider trades for progenics pharmaceuticals inc bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close progenics pharmaceuticals inc nasdaq pgnx go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus progenics pharmaceuticals inc after hours  quotes are delayed by  min jul    pm pgnx quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   insider activity individual bryce v tenbarge mr bryce v tenbarge is vice presidentcommercial at progenics pharmaceuticals inc he received his mba from the university of michigan transactions date shares transaction value copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr mark robert baker chief executive officer  director mr patrick fabbio cfo principal accounting officer  senior vp dr thomas strack vice presidentclinical affairs mr jeffrey d summer senior vice presidentstrategy  performance mr bryce v tenbarge vice presidentcommercial dr vivien wong vice presidentproduct development ms melissa down investor relations contact mr peter j crowley chairman mr bradley l campbell independent director dr karen jean ferrante independent director mr michael d kishbauch independent director ms nicole s williams independent director dr david a scheinberg independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  progenics pharmaceuticals announces appointment of bryce v tenbarge as vice president of commercial  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street progenics pharmaceuticals announces appointment of bryce v tenbarge as vice president of commercial globenewswire sep    am edt new york sept   globe newswire  progenics pharmaceuticals inc nasdaqpgnx an oncology company developing innovative medicines and other products for targeting and treating cancer today announced the appointment of bryce v tenbarge as vice president of commercial effective august   in this newly created role mr tenbarge will report to mark baker chief executive officer of progenics and will be responsible for leading all of the companys commercial activities mr tenbarge brings over fifteen years of experience in biopharmaceutical marketing most recently as vice president of marketing and commercialization at celldex therapeutics bryce is a tenured biopharmaceutical marketing executive with particular expertise in oncology said mark baker chief executive officer of progenics his proven ability to design and implement commercial infrastructure support highlyspecialized product launches and work in close collaboration with sales organizations will prove invaluable as we prepare for the potential commercial launch of our ultraorphan radiopharmaceutical candidate azedra ® and further advance our latestage prostate cancer imaging and therapeutics pipeline progenics is emerging as a leader in the development of novel oncology imaging agents and therapeutics and i am pleased to be joining the team at this important time said mr tenbarge azedra represents a potential breakthrough in the treatment of malignant pheochromocytomas and paragangliomas rare neuroendocrine cancers for which there are currently no approved therapies and the companys promising pipeline has the potential to transform how prostate cancer is diagnosed monitored and treated i look forward to working with the progenics leadership team to bring these innovative therapies to patients in need mr tenbarge joins progenics from celldex therapeutics where he served as vice president of marketing and commercialization since  from  to  he was senior director of oncology marketing at teva pharmaceuticals prior to teva he held several marketing positions of increasing responsibility at bristolmyers squibb including sales business intelligence payer and professional marketing mr tenbarge received his mba from the ross school of business at the university of michigan if you liked this article you might like  biotechs to buy this summer these companies will do well despite a range bound sector bret jensen jul    am edt what poker taught me about investing ive learned that emotions have little use at a poker table they dont in the stock market either bret jensen apr    pm edt what poker taught me about investing ive learned that emotions have little use at a poker table they dont in the stock market either bret jensen mar    am edt  smallcap biotech stars im still enthusiastic about the sector but it is critical to also be prudent bret jensen mar    pm est trending tesla is a cult stock jim cramer says amazon alphabet and a gop failure on healthcare heres where wall street stands when stocks fall and its not their fault cramers mad money recap friday  ipod nano shuffle are dead here are  other discontinued apple products can apple show amazon what earnings should look like advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers progenics pharmaceuticals announces appointment of bryce v tenbarge as vice president of commercial nasdaqpgnx             share this on delicious digg facebook linkedin twitter what is this « previous release  next release » september   progenics pharmaceuticals announces appointment of bryce v tenbarge as vice president of commercial new york sept   globe newswire  progenics pharmaceuticals inc nasdaqpgnx an oncology company developing innovative medicines and other products for targeting and treating cancer today announced the appointment of bryce v tenbarge as vice president of commercial effective august   in this newly created role mr tenbarge will report to mark baker chief executive officer of progenics and will be responsible for leading all of the companys commercial activities mr tenbarge brings over fifteen years of experience in biopharmaceutical marketing most recently as vice president of marketing and commercialization at celldex therapeutics bryce is a tenured biopharmaceutical marketing executive with particular expertise in oncology said mark baker chief executive officer of progenics his proven ability to design and implement commercial infrastructure support highlyspecialized product launches and work in close collaboration with sales organizations will prove invaluable as we prepare for the potential commercial launch of our ultraorphan radiopharmaceutical candidate azedra® and further advance our latestage prostate cancer imaging and therapeutics pipeline progenics is emerging as a leader in the development of novel oncology imaging agents and therapeutics and i am pleased to be joining the team at this important time said mr tenbarge azedra represents a potential breakthrough in the treatment of malignant pheochromocytomas and paragangliomas rare neuroendocrine cancers for which there are currently no approved therapies and the companys promising pipeline has the potential to transform how prostate cancer is diagnosed monitored and treated i look forward to working with the progenics leadership team to bring these innovative therapies to patients in need mr tenbarge joins progenics from celldex therapeutics where he served as vice president of marketing and commercialization since  from  to  he was senior director of oncology marketing at teva pharmaceuticals prior to teva he held several marketing positions of increasing responsibility at bristolmyers squibb including sales business intelligence payer and professional marketing mr tenbarge received his mba from the ross school of business at the university of michigan about progenics progenics pharmaceuticals inc is developing innovative medicines and other products for targeting and treating cancer with a pipeline that includes several product candidates in laterstage clinical development these products in development include therapeutic agents designed to precisely target cancer azedra® and  and psmatargeted imaging agents for prostate cancer  and pyl™ intended to enable clinicians and patients to accurately visualize and manage their disease progenics recently entered into an agreement with a subsidiary of bayer ag granting bayer exclusive worldwide rights to develop and commercialize products using our psma antibody technology in combination with alphaemitting radionuclides  in addition in late  progenics acquired exini diagnostics ab a leader in the development of advanced artificial intelligencebased imaging analysis tools and solutions for medical decision support the acquisition of exini complements progenics strategy to support its imaging and therapeutic agents with sophisticated analytical tools and other technologies to help physicians and patients visualize understand target and treat cancer  progenics first commercial product relistor® methylnaltrexone bromide for opioidinduced constipation is partnered with and marketed by valeant pharmaceuticals international inc this press release may contain projections and other forwardlooking statements regarding future events statements contained in this communication that refer to progenics estimated or anticipated future results or other nonhistorical facts are forwardlooking statements that reflect progenics current perspective of existing trends and information as of the date of this communication forward looking statements generally will be accompanied by words such as anticipate believe plan could should estimate expect forecast outlook guidance intend may might will possible potential predict project or other similar words phrases or expressions such statements are predictions only and are subject to risks and uncertainties that could cause actual events or results to differ materially these risks and uncertainties include among others the cost timing and unpredictability of results of clinical trials and other development activities and collaborations such as the phase  clinical program for  our ability to successfully integrate exini diagnostics ab and to develop and commercialize its products the unpredictability of the duration and results of regulatory review of new drug applications and investigational ndas market acceptance for approved products the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby generic and other competition the possible impairment of inability to obtain and costs of obtaining intellectual property rights possible product safety or efficacy concerns general business financial and accounting matters litigation and other risks more information concerning progenics and such risks and uncertainties is available on its website and in its press releases and reports it files with the us securities and exchange commission progenics is providing the information in this press release as of its date and except as expressly required by law progenics disclaims any intent or obligation to update or revise any forwardlooking statements whether as a result of new information future events or circumstances or otherwise additional information concerning progenics and its business may be available in press releases or other public announcements and public filings made after this release for more information please visit wwwprogenicscom please follow us on linkedin® information on or accessed through our website or social media sites is not included in the companys sec filings pgnxfcontact melissa downs investor relations   mdownsprogenicscom close window  back to top delicious digg facebook linkedin twitter copyright  progenics pharmaceuticals inc progenics pharmaceuticals announces appointment of bryce v tenbarge as vice president of commercial july edition of canna investorshub magazine now available support   newswire  home  log in boards stocks commodities forex cryptocurrency the lounge hot breakout boards ihub my stocks activity ticker buzz cloud most read most posted most followed members recent news active boards site stats new boards cannabis stocks tools data tools  charts trader alerts trades portfolio top lists price  news alerts commodities markets in d newswire more tools  newsletters my image gallery advanced search videos all news stock screener news filter live charts live news live desktop forex prices commodities etf center educational channel personal finance qa streamer level  follow feed quotechartlevel tradesnewsfinancialshistoricaltechnical analysismessage boardprogenics pharmaceuticals inc mm nasdaq progenics pharmaceuticals announces appointment of bryce v tenbarge as vice president of commercial date    am source  globenewswire inc stock  progenics pharmaceuticals inc mm pgnx quote       pm progenics pharmaceuticals announces appointment of bryce v tenbarge as vice president of commercialtweet print progenics pharmaceuticals inc mm nasdaqpgnxhistorical stock chart  year  from jul  to jul  progenics pharmaceuticals inc nasdaqpgnx an oncology company developing innovative medicines and other products for targeting and treating cancer today announced the appointment of bryce v tenbarge as vice president of commercial effective august   in this newly created role mr tenbarge will report to mark baker chief executive officer of progenics and will be responsible for leading all of the company’s commercial activities mr tenbarge brings over fifteen years of experience in biopharmaceutical marketing most recently as vice president of marketing and commercialization at celldex therapeutics “bryce is a tenured biopharmaceutical marketing executive with particular expertise in oncology” said mark baker chief executive officer of progenics “his proven ability to design and implement commercial infrastructure support highlyspecialized product launches and work in close collaboration with sales organizations will prove invaluable as we prepare for the potential commercial launch of our ultraorphan radiopharmaceutical candidate azedra® and further advance our latestage prostate cancer imaging and therapeutics pipeline” “progenics is emerging as a leader in the development of novel oncology imaging agents and therapeutics and i am pleased to be joining the team at this important time” said mr tenbarge “azedra represents a potential breakthrough in the treatment of malignant pheochromocytomas and paragangliomas rare neuroendocrine cancers for which there are currently no approved therapies and the company’s promising pipeline has the potential to transform how prostate cancer is diagnosed monitored and treated i look forward to working with the progenics leadership team to bring these innovative therapies to patients in need” mr tenbarge joins progenics from celldex therapeutics where he served as vice president of marketing and commercialization since  from  to  he was senior director of oncology marketing at teva pharmaceuticals prior to teva he held several marketing positions of increasing responsibility at bristolmyers squibb including sales business intelligence payer and professional marketing mr tenbarge received his mba from the ross school of business at the university of michigan about progenics progenics pharmaceuticals inc is developing innovative medicines and other products for targeting and treating cancer with a pipeline that includes several product candidates in laterstage clinical development these products in development include therapeutic agents designed to precisely target cancer azedra® and  and psmatargeted imaging agents for prostate cancer  and pyl™ intended to enable clinicians and patients to accurately visualize and manage their disease progenics recently entered into an agreement with a subsidiary of bayer ag granting bayer exclusive worldwide rights to develop and commercialize products using our psma antibody technology in combination with alphaemitting radionuclides  in addition in late  progenics acquired exini diagnostics ab a leader in the development of advanced artificial intelligencebased imaging analysis tools and solutions for medical decision support the acquisition of exini complements progenics strategy to support its imaging and therapeutic agents with sophisticated analytical tools and other technologies to help physicians and patients visualize understand target and treat cancer  progenics first commercial product relistor® methylnaltrexone bromide for opioidinduced constipation is partnered with and marketed by valeant pharmaceuticals international inc this press release may contain projections and other forwardlooking statements regarding future events statements contained in this communication that refer to progenics estimated or anticipated future results or other nonhistorical facts are forwardlooking statements that reflect progenics current perspective of existing trends and information as of the date of this communication forward looking statements generally will be accompanied by words such as anticipate believe plan could should estimate expect forecast outlook guidance intend may might will possible potential predict project or other similar words phrases or expressions such statements are predictions only and are subject to risks and uncertainties that could cause actual events or results to differ materially these risks and uncertainties include among others the cost timing and unpredictability of results of clinical trials and other development activities and collaborations such as the phase  clinical program for  our ability to successfully integrate exini diagnostics ab and to develop and commercialize its products the unpredictability of the duration and results of regulatory review of new drug applications and investigational ndas market acceptance for approved products the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby generic and other competition the possible impairment of inability to obtain and costs of obtaining intellectual property rights possible product safety or efficacy concerns general business financial and accounting matters litigation and other risks more information concerning progenics and such risks and uncertainties is available on its website and in its press releases and reports it files with the us securities and exchange commission progenics is providing the information in this press release as of its date and except as expressly required by law progenics disclaims any intent or obligation to update or revise any forwardlooking statements whether as a result of new information future events or circumstances or otherwise additional information concerning progenics and its business may be available in press releases or other public announcements and public filings made after this release for more information please visit wwwprogenicscom please follow us on linkedin® information on or accessed through our website or social media sites is not included in the companys sec filings pgnxf contact melissa downs investor relations   mdownsprogenicscom latest pgnx messages view more posts remove from favorites add to favorites  message board see more message board posts your recent history lse gkp gulf keyst lse qpp quindell ftse ukx ftse  lse iof iofina fx gbpusd uk sterlin stocks youve viewed will appear in this box letting you easily return to quotes youve seen previouslyregister now to create your own custom streaming stock watchlist nyse amex and asx quotes are delayed by at least  minutesall other quotes are delayed by at least  minutes unless otherwise stated bryce tenbarge  progenics pharmaceuticals inc  email vp commercial progenicscom login  day free trial bryce tenbarge progenics pharmaceuticals inc vp commercial export one world trade center new york ny  email format for progenicscom direct phone not available type public employees    revenue    million industry biotechhealthcaremajor drugs sic code   pharmaceutical preparations biography need to know bryce tenbarges email phone numbers linkedin profile wiki twitter username and biography you can find contact information on progenics pharmaceuticals incs lead profile bryce tenbarge is the vp commercial for progenics pharmaceuticals inc an organization which has its base in new york ny one can also find progenics pharmaceuticals inc email addresses on their lead profile with the progenicscom url major drugs is progenics pharmaceuticals incs industry within the lead database some possible email formats for bryce tenbarge are btenbargeprogenicscom brycetenbargeprogenicscom bryceprogenicscom and brycetenbargeprogenicscom if you sign up for our free trial you will see our emailprogenicscom addresses similar people bryce tabb  executive trying to find bryce tabbs email wiki phone numbers twitter biography and linkedin data you can check out trammell crow residentials profile on lead where you can also get tcresidentialcom contact information trammell crow residential is an organization centered in carlsbad ca which you can find on lead under the real estate category bryce tabb is their development analyst some possible email formats for bryce tabb are btabbtcresidentialcom brycetabbtcresidentialcom brycetcresidentialcom and brycetabbtcresidentialcom if you sign up for our free trial you will see our emailtcresidentialcom addresses bryce tache  executive their manager diversity  inclusion is bryce tache their lead profile is categorized under the information services industry if youre checking for iron mountain incorporated email addresses these are also available on lead with the ironmountaincom email addresses and possibly bryce taches email iron mountain incorporated is based in boston ma you can also get bryce taches linkedin info twitter data phone numbers wiki and biography on their lead profile their contact information is filed under the information services category some possible email formats for bryce tache are btacheironmountaincom brycetacheironmountaincom bryceironmountaincom and brycetacheironmountaincom if you sign up for our free trial you will see our emailironmountaincom addresses bryce tafelski  executive have you been looking for contact information like phone numbers and emails on bryce tafelski lead provides data on him which include twitter linkedin url wiki and biography there is also insight global email addresses within the insightglobalnet profile so bryce tafelskis email could be included bryce tafelski is part of the insight global which has its main offices in homewood al currently holds the post of sales manager you can find the company data on lead under the technology consultingservices industry some possible email formats for bryce tafelski are btafelskiinsightglobalnet brycetafelskiinsightglobalnet bryceinsightglobalnet and brycetafelskiinsightglobalnet if you sign up for our free trial you will see our emailinsightglobalnet addresses similar employees mark baker  executive a new york nybased organization progenics pharmaceuticals inc is just one of the many lead profiles that you can find contact information like phone numbers and emails their profile includes progenicscom email addresses as well as details on mark bakers email the organizations chief executive officer their profile can be found in major drugs category if you also need twitter facebook linkedin wiki and biography details for mark baker you can also find them in lead some possible email formats for mark baker are mbakerprogenicscom markbakerprogenicscom markprogenicscom and markbakerprogenicscom if you sign up for our free trial you will see our emailprogenicscom addresses peter crowley  executive progenics pharmaceuticals incs chairman is where peter crowley is employed on the other hand the organizations ceo is  they are based in new york ny and you can find their lead profile filed under the major drugs industry peter crowleys profile contains twitter phone numbers linkedin wiki and contact information and you can also find other progenics pharmaceuticals inc email addresses on lead with the progenicscom domain some possible email formats for peter crowley are pcrowleyprogenicscom petercrowleyprogenicscom peterprogenicscom and petercrowleyprogenicscom if you sign up for our free trial you will see our emailprogenicscom addresses ann assumma  other is progenics pharmaceuticals incs ceo their vice president regulatory affairs is ann assumma their lead profile is categorized under the major drugs industry if youre checking for progenics pharmaceuticals inc email addresses these are also available on lead with the progenicscom email format and possibly ann assummas email progenics pharmaceuticals inc is based in new york ny you can also get ann assummas linkedin info twitter phone numbers wiki and biography on their lead profile their contact information is filed under the major drugs category some possible email formats for ann assumma are aassummaprogenicscom annassummaprogenicscom annprogenicscom and annassummaprogenicscom if you sign up for our free trial you will see our emailprogenicscom addresses people directory  bryce tenbarge progenics announces appointment of bryce v tenbarge as vice president of commercial employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       progenics pgnx announces appointment of bryce v tenbarge as vice president of commercial tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs new york sept   globe newswire  progenics pharmaceuticals inc nasdaqpgnx an oncology company developing innovative medicines and other products for targeting and treating cancer today announced the appointment of bryce v tenbarge as vice president of commercial effective august   in this newly created role mr tenbarge will report to mark baker chief executive officer of progenics and will be responsible for leading all of the company’s commercial activities mr tenbarge brings over fifteen years of experience in biopharmaceutical marketing most recently as vice president of marketing and commercialization at celldex therapeutics “bryce is a tenured biopharmaceutical marketing executive with particular expertise in oncology” said mark baker chief executive officer of progenics “his proven ability to design and implement commercial infrastructure support highlyspecialized product launches and work in close collaboration with sales organizations will prove invaluable as we prepare for the potential commercial launch of our ultraorphan radiopharmaceutical candidate azedra® and further advance our latestage prostate cancer imaging and therapeutics pipeline” “progenics is emerging as a leader in the development of novel oncology imaging agents and therapeutics and i am pleased to be joining the team at this important time” said mr tenbarge “azedra represents a potential breakthrough in the treatment of malignant pheochromocytomas and paragangliomas rare neuroendocrine cancers for which there are currently no approved therapies and the company’s promising pipeline has the potential to transform how prostate cancer is diagnosed monitored and treated i look forward to working with the progenics leadership team to bring these innovative therapies to patients in need” mr tenbarge joins progenics from celldex therapeutics where he served as vice president of marketing and commercialization since  from  to  he was senior director of oncology marketing at teva pharmaceuticals prior to teva he held several marketing positions of increasing responsibility at bristolmyers squibb including sales business intelligence payer and professional marketing mr tenbarge received his mba from the ross school of business at the university of michigan about progenics progenics pharmaceuticals inc is developing innovative medicines and other products for targeting and treating cancer with a pipeline that includes several product candidates in laterstage clinical development these products in development include therapeutic agents designed to precisely target cancer azedra® and  and psmatargeted imaging agents for prostate cancer  and pyl™ intended to enable clinicians and patients to accurately visualize and manage their disease progenics recently entered into an agreement with a subsidiary of bayer ag granting bayer exclusive worldwide rights to develop and commercialize products using our psma antibody technology in combination with alphaemitting radionuclides  in addition in late  progenics acquired exini diagnostics ab a leader in the development of advanced artificial intelligencebased imaging analysis tools and solutions for medical decision support the acquisition of exini complements progenics strategy to support its imaging and therapeutic agents with sophisticated analytical tools and other technologies to help physicians and patients visualize understand target and treat cancer  progenics first commercial product relistor® methylnaltrexone bromide for opioidinduced constipation is partnered with and marketed by valeant pharmaceuticals international inc this press release may contain projections and other forwardlooking statements regarding future events statements contained in this communication that refer to progenics estimated or anticipated future results or other nonhistorical facts are forwardlooking statements that reflect progenics current perspective of existing trends and information as of the date of this communication forward looking statements generally will be accompanied by words such as anticipate believe plan could should estimate expect forecast outlook guidance intend may might will possible potential predict project or other similar words phrases or expressions such statements are predictions only and are subject to risks and uncertainties that could cause actual events or results to differ materially these risks and uncertainties include among others the cost timing and unpredictability of results of clinical trials and other development activities and collaborations such as the phase  clinical program for  our ability to successfully integrate exini diagnostics ab and to develop and commercialize its products the unpredictability of the duration and results of regulatory review of new drug applications and investigational ndas market acceptance for approved products the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby generic and other competition the possible impairment of inability to obtain and costs of obtaining intellectual property rights possible product safety or efficacy concerns general business financial and accounting matters litigation and other risks more information concerning progenics and such risks and uncertainties is available on its website and in its press releases and reports it files with the us securities and exchange commission progenics is providing the information in this press release as of its date and except as expressly required by law progenics disclaims any intent or obligation to update or revise any forwardlooking statements whether as a result of new information future events or circumstances or otherwise additional information concerning progenics and its business may be available in press releases or other public announcements and public filings made after this release for more information please visit wwwprogenicscom please follow us on linkedin® information on or accessed through our website or social media sites is not included in the companys sec filings pgnxfcontact melissa downs investor relations   mdownsprogenicscom read at biospacecom related news valeant vrx and progenics pgnx announce the us commercial launch of fdaapproved relistor tablets how merck  co mrks cio is quietly changing the techstartup world valeant vrx progenics pgnx shares climb on constipation drug approval is there anyone the drug industry hates more than this aids activist progenics pgnx receives  million milestone payment following fda approval of relistor tablets for the treatment of opioidinduced constipation in adults with chronic noncancer pain fivefigure salaries big hair pharma  progenics pgnx signs commercial license agreement with selexis sa for use of proprietary cell line and suretechnology platform kalobios kbio postshkreli vows maniacal focus on rd and transparency progenics pgnx announces second quarter  financial and business results novartis ag nvs purges senior execs as it carts itself off please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • progenics pharmaceuticals inc   • biotechpharma  personnel                 bryce tenbarge on crowdrise skip to content close system alert message bryce tenbarge royalty crests comments to leave a comment login or signup shaun says dear friends thank you all … dear friends thank you all so very much for your kindness generosity and prayers for the genuardi family during this most difficult time for them the love and support for the family are overwhelming thanks to you we met our fundraising goal we plan to keep this fundraiser active for a period of time as many people continue to pass along the web link to others with much gratitude i thank you sincerely shaun mickus sandshore school cub scout pack  den  leader  years ago see more   about bryce tenbarge newtown pa united states crowdrising since sep   stuff about me the person who created this page is probably preparing something riveting to post about everything theyre doing to give back we recommend you sit at your computer and hit refresh over and over until their story goes live you should also scroll down and see if they have a fundraiser going so you can support em brycetenbarge vote cr impact points click the vote button to give bryce  crowdrise impact points cips vote for the volunteers and fundraisers that are answering the call to service raising money for charity and making an impact for their causes come back and vote every months cips can earn you the highly coveted highly respected crowdrise royalty status cr impact points if youre seeing the grey vote button you should feel great about yourself it means you already voted for bryce this month come back next month and vote again if you still love bryce thanks to your vote bryce earned  crowdrise impact points cips cips can earn you the highly coveted highly respected crowdrise royalty status  total impact points  money raised share this page share tweet bryce tenbarges fundraisers im working on creating my first super compelling fundraiser so please keep hitting refresh over and over until my first fundraiser shows up or just wait for me to email you about it hey there in progress were setting up your fundraiser page right now it will take anywhere from  seconds to  seconds